{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:54:27Z","timestamp":1793836467245,"version":"4.6.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. Daratumumab-based regimens achieve deep hematologic and organ responses, offering a new therapeutic backbone. Early identification, correct fibril typing, challenges of the very advanced patient, and lack of therapies to remove amyloid deposits remain under study, but are, as yet, elusive. We review the progress of treatment in AL amyloidosis, the impact of daratumumab, and the next steps after treatment.<\/jats:p>","DOI":"10.1182\/blood.2021014613","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T17:52:56Z","timestamp":1651686776000},"page":"2317-2322","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Daratumumab in AL amyloidosis"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-7237","authenticated-orcid":false,"given":"Ashutosh D.","family":"Wechalekar","sequence":"first","affiliation":[{"name":"1National Amyloidosis Center, University College London (Royal Free Campus), London, United Kingdom"},{"name":"2Department of Hematology, University College London Hospitals, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[{"name":"3Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2022120116264468000_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2022120116264468000_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2022120116264468000_bib3","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"issue":"16","key":"2022120116264468000_bib4","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2022120116264468000_bib5","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A\u00a0trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2022120116264468000_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2022120116264468000_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","article-title":"Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis","volume":"109","author":"Wechalekar","year":"2007","journal-title":"Blood"},{"issue":"15","key":"2022120116264468000_bib8","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2022120116264468000_bib9","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2014-04-568329","article-title":"Long-term follow-up from a phase 1\/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis","volume":"124","author":"Reece","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2022120116264468000_bib10","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2022120116264468000_bib11","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"25","key":"2022120116264468000_bib12","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A\u00a0prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2022120116264468000_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2022120116264468000_bib14","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2022120116264468000_bib15","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and Survival Trends in Amyloidosis, 1987-2019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2022120116264468000_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"2022120116264468000_bib17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/qjmed\/hcr105","article-title":"Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects","volume":"104","author":"Dubrey","year":"2011","journal-title":"QJM"},{"issue":"12","key":"2022120116264468000_bib18","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A\u00a0matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"2022120116264468000_bib19","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ajh.25940","article-title":"Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio","volume":"95","author":"Muchtar","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"2022120116264468000_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-021-00511-6","article-title":"Detection of minimal residual disease by next generation sequencing in AL amyloidosis","volume":"11","author":"Sarosiek","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2022120116264468000_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","author":"Palladini","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"2022120116264468000_bib22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/bloodadvances.2019001331","article-title":"Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis","volume":"4","author":"Staron","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2022120116264468000_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-021-00510-7","article-title":"Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib","volume":"11","author":"Ravichandran","year":"2021","journal-title":"Blood Cancer J"},{"issue":"15","key":"2022120116264468000_bib24","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2016-06-722496","article-title":"First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2022120116264468000_bib25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2022120116264468000_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"2022120116264468000_bib27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/ejh.13552","article-title":"The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience","volume":"106","author":"Lee","year":"2021","journal-title":"Eur J Haematol"},{"issue":"3","key":"2022120116264468000_bib28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/bloodadvances.2019000776","article-title":"Organ responses with daratumumab therapy in previously treated AL amyloidosis","volume":"4","author":"Chung","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2022120116264468000_bib29","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.16282","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Van de Wyngaert","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2022120116264468000_bib30","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/bloodadvances.2020001553","article-title":"Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function","volume":"4","author":"Milani","year":"2020","journal-title":"Blood Adv"},{"issue":"18","key":"2022120116264468000_bib31","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with\u00a0nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2022120116264468000_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13506129.2020.1730791","article-title":"Treatment with daratumumab in patients with relapsed\/refractory AL amyloidosis: a multicentric retrospective study and review of the literature","volume":"27","author":"Lecumberri","year":"2020","journal-title":"Amyloid"},{"issue":"18","key":"2022120116264468000_bib33","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2022120116264468000_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26399","article-title":"Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab","volume":"97","author":"Szalat","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"2022120116264468000_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/13506129.2020.1765768","article-title":"Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed\/refractory AL amyloidosis","volume":"27","author":"Cohen","year":"2020","journal-title":"Amyloid"},{"issue":"2","key":"2022120116264468000_bib36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ejh.13535","article-title":"Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review","volume":"106","author":"Shragai","year":"2021","journal-title":"Eur J Haematol"},{"issue":"18","key":"2022120116264468000_bib37","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A\u00a0prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2022120116264468000_bib38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jcph.1994","article-title":"Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis","volume":"62","author":"Luo","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"suppl 1","key":"2022120116264468000_bib39","article-title":"Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study","volume":"138","author":"Comenzo","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2022120116264468000_bib40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis","volume":"34","author":"Muchtar","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"2022120116264468000_bib41","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly\u00a0diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2022120116264468000_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory\u00a0AL\u00a0amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2022120116264468000_bib43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41375-020-0800-6","article-title":"Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis","volume":"35","author":"Cuenca","year":"2021","journal-title":"Leukemia"},{"issue":"25","key":"2022120116264468000_bib44","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2022120116264468000_bib45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11307-021-01681-2","article-title":"First in Human Evaluation and Dosimetry Calculations for Peptide 124I-p5\u00a0+ 14-a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET\/CT Imaging","volume":"24","author":"Wall","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"2022120116264468000_bib46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/13506129.2018.1552852","article-title":"A\u00a0pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement","volume":"25","author":"Manwani","year":"2018","journal-title":"Amyloid"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/22\/2317\/2019179\/blood_bld-2021-014613-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/22\/2317\/2019179\/blood_bld-2021-014613-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:59:11Z","timestamp":1669921151000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/22\/2317\/485153\/Daratumumab-in-AL-amyloidosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":46,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014613","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}